Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy as determined by medical history and physical examination.~2. Age 19 through 38 years at the time of screening.~3. Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.~4. Weight less than or equal to (\<=) 10 kilogram (kg) with body mass index (BMI) less than (\<) 32 kilogram per meter square (kg/m\^2).~5. Normotensive (systolic blood pressure \[BP\] \<150 millimeters of mercury (mmHg) and diastolic BP \< 90 mmHg).~6. Females of childbearing age using contraception.~7. Males who are sexually active with a female partner of childbearing potential, using contraception.~8. Sero-suitable (that is, low serum RSV neutralizing antibody titre) for RSV infection.~Exclusion Criteria:~Current medical conditions as follows:~1. Clinical evidence of chronic pulmonary disease or any use of a bronchodilator or other asthma medication.~2. Current smoker unwilling/unable to desist for the quarantine phase of the study.~3. History or clinical evidence of recurrent lower respiratory tract infection.~4. Evidence of infection with hepatitis A, B, or C virus or human immunodeficiency virus (HIV) by serology.~   Medical history as follows:~5. History of immunodeficiency.~6. History of chronic sinusitis.~7. History of frequent epistaxis.~8. History of or current diagnosis of diabetes.~9. Prior/concomitant therapy including~   * Receipt of any systemic chemotherapeutic agent at any time;~  * Receipt of systemic glucocorticoids within 1 month, or any other immunosuppressive drug within 6 months prior to challenge.~  * Receipt of any investigational drug within 6 months prior to dose or concurrent enrolment in another clinical study.~  * Prior participation in a clinical trial of any experimental RSV viral challenge delivered directly to the respiratory tract at any time, or any other respiratory virus challenge within 1 year prior to dose.~10. Nursing mother.~11. Alcohol or drug addiction/abuse within the past 2 years.~12. A positive urine Class A drug or alcohol screen unless there is a medical reason.~13. History of seasonal hay fever or seasonal allergies.~14. Employees of the clinical study site or sponsor, any other individuals involved with the conduct of the study, or immediate family members of such individuals.~15. Health care workers anticipated to have patient contact within 2 weeks after viral challenge.~16. Participants who, for an additional 2 weeks after discharge from the isolation facility, are likely to have contact with a household member or close contact with someone who is: (a) less than 3 years of age; (b) any person with any known immunodeficiency; (c) any person receiving immunosuppressant medications; (d) any person undergoing or soon to undergo cancer chemotherapy within 28 days of challenge; (e) any person who has diagnosed emphysema or COPD, is elderly residing in a nursing home, or with severe lung disease or medical condition; or (f) any person who has received a transplant (bone marrow or solid organ).~17. As a result of the medical interview, physical examination, or screening investigations, the investigator(s) considers the participant unfit for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
- MEDI-557 (Type: EXPERIMENTAL): Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).